EAM
NSRX icon

Empery Asset Management’s Nasus Pharma NSRX Stock Holding History

Empery Asset Management’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,803
Closed -$102K – 43
2026
Q1 		$102K Buy
+45,803
New +$236K 0.12% 21

Other funds holding NSRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Cable Car Capital
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Empery Asset Management's NSRX Position: Q2 2026 in Review

Empery Asset Management sold out of Nasus Pharma (NSRX) in Q2 2026, closing a stake of 45,803 shares — an estimated $102K sold.

Empery Asset Management first reported a position in NSRX in Q1 2026 and held it in 1 quarter. The position peaked at $102K in Q1 2026. 10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

  • Empery Asset Management reported no remaining Nasus Pharma position as of Q2 2026 after selling out during the quarter.
  • Empery Asset Management sold 45,803 Nasus Pharma shares in Q2 2026, an estimated $102K.
  • Empery Asset Management first reported a position in Nasus Pharma in Q1 2026 and held it in 1 quarter.
  • Empery Asset Management's Nasus Pharma position peaked at $102K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.